GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aileron Therapeutics Inc (NAS:ALRN) » Definitions » PB Ratio

Aileron Therapeutics (Aileron Therapeutics) PB Ratio : 2.96 (As of May. 02, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Aileron Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-02), Aileron Therapeutics's share price is $4.17. Aileron Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $1.41. Hence, Aileron Therapeutics's PB Ratio of today is 2.96.

The historical rank and industry rank for Aileron Therapeutics's PB Ratio or its related term are showing as below:

ALRN' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 269.2
Current: 2.95

During the past 9 years, Aileron Therapeutics's highest PB Ratio was 269.20. The lowest was 0.00. And the median was 0.00.

ALRN's PB Ratio is ranked worse than
57.21% of 1311 companies
in the Biotechnology industry
Industry Median: 2.46 vs ALRN: 2.95

During the past 12 months, Aileron Therapeutics's average Book Value Per Share Growth Rate was -65.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -36.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -38.90% per year.

During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Aileron Therapeutics was -28.50% per year. The lowest was -55.90% per year. And the median was -32.95% per year.

Back to Basics: PB Ratio


Aileron Therapeutics PB Ratio Historical Data

The historical data trend for Aileron Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aileron Therapeutics PB Ratio Chart

Aileron Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only 0.99 3.75 1.16 0.58 2.16

Aileron Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.39 0.64 0.62 2.16

Competitive Comparison of Aileron Therapeutics's PB Ratio

For the Biotechnology subindustry, Aileron Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aileron Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aileron Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Aileron Therapeutics's PB Ratio falls into.



Aileron Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Aileron Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=4.17/1.41
=2.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Aileron Therapeutics  (NAS:ALRN) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Aileron Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Aileron Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aileron Therapeutics (Aileron Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
285 Summer Street, Unit 101, Boston, MA, USA, 02210
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects.
Executives
James Brian Windsor officer: See Remarks 2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746
William Fairey director C/O CHEMOCENTRYX, INC., 850 MAUDE AVE., MOUNTAIN VIEW CA 94043
Alan A Musso director FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Susan L. Drexler officer: See Remarks 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Muneer A Satter 10 percent owner C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Reinhard J. Ambros director C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139
Von Rickenbach Josef H director C/O PAREXEL INTERNATIONAL CORPORATION, WALTHAM MA 02451-1163
Jeffrey Allen Bailey director BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Vojo Vukovic officer: SVP, Chief Medical Officer C/O SYNTA PHARMACEUTICALS CORP., 45 HARTWELL AVENUE, LEXINGTON MA 02421
Kathryn Gregory officer: SVP, Chief Business Officer 305 THAYER POND ROAD, WILTON CT 06897
William Mckee director
Nolan Howard Sigal director 941 BERRY AVENUE, LOS ALTOS CA 94024
Novartis Bioventures Ltd 10 percent owner C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
Rick Wanstall officer: VP, Finance and Operations C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472
Longenecker John P Phd officer: President and CEO 10445 PACIFIC CENTER CT, SAN DIEGO CA 92121

Aileron Therapeutics (Aileron Therapeutics) Headlines

From GuruFocus

Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022

By GuruFocusNews GuruFocusNews 06-22-2022